Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

314
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
314
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

280
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
280

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Mar 17, 2026

Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
07:06

Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

Published on: May 14, 2020

5.6K

New FDA Center May Speed Approval Process

    Cancer Discovery
    |July 16, 2016
    PubMed
    Summary

    The US Food and Drug Administration (FDA) established the Oncology Center of Excellence to streamline cancer drug, biologic, and device approvals. Dr. Richard Pazdur will lead this new initiative.

    Area of Science:

    • Oncology
    • Regulatory Science
    • Drug Development

    Background:

    • The US Food and Drug Administration (FDA) currently has separate divisions for evaluating cancer drugs, biologics, and devices.
    • This can lead to fragmented review processes and potential delays in bringing new cancer therapies to patients.

    Purpose of the Study:

    • To announce the establishment of the FDA's Oncology Center of Excellence.
    • To consolidate the review and approval pathways for oncology therapeutics and medical devices.

    Main Methods:

    • Not applicable for this announcement.
    • N/A

    Main Results:

    • The FDA has officially launched the Oncology Center of Excellence.

    More Related Videos

    Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
    06:18

    Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

    Published on: August 18, 2023

    3.9K
    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    08:47

    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

    Published on: December 16, 2022

    2.9K

    Related Experiment Videos

    Last Updated: Mar 17, 2026

    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
    07:06

    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

    Published on: May 14, 2020

    5.6K
    Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
    06:18

    Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

    Published on: August 18, 2023

    3.9K
    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    08:47

    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

    Published on: December 16, 2022

    2.9K
  • Richard Pazdur, MD, has been appointed as the acting director.

    • Conclusions:

    • The new center aims to improve the efficiency and coordination of cancer product approvals.
    • This consolidation is expected to facilitate faster patient access to novel cancer treatments and technologies.